Home » Newsletters » BioWorld Asia

BioWorld Asia

March 3, 1999

View Archived Issues

Narcolepsy Research Locates Potential Gene-Marker Cause

MorphoSys IPO To Value Antibody Firm At US$85M

Biota Flu-Drug Rejection Sends Stock Into Nosedive

Cortecs Ending Phase III Trials Early To Gather Data

Biostar Subsidiary To Target Hormone-Dependent Cancers

Sanofi Doubles Funding For Cerep In Targets Deal

PPL Therapeutics' Phase II Anti-Infective Data Positive

GlycoDesign Cancer Drug May Block Chemo Damage

U.K. Sector Enlarging Fast, Says BioIndustry Association

Flamel Blames R&D Costs, Phase III Trials For Net Loss

Pharming Revenues Rise; Plans Pompe's Drug Launch

Plant Genomics Program May Seek More Partners

Nations Clash In Cartagena Over Biosafety Food Rules

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...